Synergistic Peptide-based Vaccination Systems

Publication ID: 24-11857615_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Peptide-based Vaccination Systems,” Published Technical Disclosure No. 24-11857615_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857615_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,615.

Summary of the Inventive Concept

Integrating peptide-based vaccines with AI, IoT, blockchain, and nanomaterials to create powerful, personalized, and secure vaccination systems.

Background and Problem Solved

The original patent disclosed peptide-based vaccines for antimicrobial prophylaxis and therapy, but it had limitations in terms of personalization, data tracking, and security. The new inventive concept addresses these limitations by combining the peptide-based vaccines with cutting-edge technologies to create a more effective, efficient, and secure system.

Detailed Description of the Inventive Concept

The inventive concept integrates a peptide-based vaccine with an AI-powered analytics engine for tracking and predicting immune responses, a blockchain-based secure data storage module for storing vaccination records and tracking vaccine efficacy, and an IoT-enabled monitoring device for real-time monitoring of vaccine administration and efficacy. The system can be further personalized by optimizing peptide sequences using machine learning algorithms and tailoring vaccination schedules to an individual's genetic profile.

Novelty and Inventive Step

The new claims introduce a synergistic combination of peptide-based vaccines with AI, IoT, blockchain, and nanomaterials, which provides a non-obvious solution to the limitations of the original patent. The integration of these technologies enables a more effective, efficient, and secure vaccination system that is not anticipated by the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include using different AI algorithms for analytics, incorporating additional sensors or monitoring devices, or integrating with existing healthcare infrastructure. Variations could include using different peptide sequences, adjuvants, or delivery vehicles, or applying the system to different diseases or applications.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the vaccine and pharmaceutical industries, particularly in the areas of personalized medicine, infectious disease prevention, and antimicrobial resistance. The system's ability to provide secure, real-time tracking and monitoring of vaccine efficacy and administration could also have applications in public health and epidemiology.

CPC Classifications

SectionClassGroup
A A61 A61K39/104
C C07 C07K14/212
A A61 A61K2039/543
A A61 A61K2039/55505
A A61 A61K2039/55566
G G01 G01N2333/22
G G01 G01N2469/20

Original Patent Information

Patent NumberUS 11,857,615
TitlePeptides derived from Acinetobacter baumannii and their use in vaccination
Assignee(s)Evaxion Biotech A/S